You are leaving Smmttx.com

You have selected a link that will take you to a site maintained by a third party who is solely responsible
for its contents.

Summit Therapeutics, Inc., is not responsible for the privacy notice of any third-party websites. We encourage you to read the privacy notice of every website you visit.

To stay on Summit’s website, click “Cancel” or click “Continue” to proceed.

HARMONi-3

HARMONi-3 Phase 3 Clinical Trial

 

Have You or Someone You Love Been Diagnosed with Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)? If yes, there is a phase 3 clinical trial called HARMONi-3 you may want to ask your doctor about.

HARMONi-3 is a randomized, controlled, multiregional phase 3 clinical trial of ivonescimab combined with chemotherapy versus pembrolizumab combined with chemotherapy for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC).

 

What is the purpose of this clinical trial?

  • The purpose of this phase 3 clinical trial is to measure overall survival (OS) and safety of ivonescimab when combined with chemotherapy compared to pembrolizumab combined with chemotherapy.

What is the clinical trial drug, ivonescimab?

  • Ivonescimab is an investigational bispecific antibody, which may simultaneously block two separate targets in the body; blocking these targets may decrease the cancer cells ability to live, grow, and spread.

Are you eligible for this clinical trial?

  • You may be eligible if you have been diagnosed with metastatic squamous NSCLC and you have not received any prior therapy for NSCLC in the metastatic setting. You cannot have any known actionable genomic alterations which include EGFR, ALK, ROS1.
  • Please talk with your doctor if you are interested to determine if you are eligible.

If you are eligible, what is involved?
Your doctor can provide you with additional information but here are a few things to know:

  • Once enrolled in the clinical trial, you will visit the clinic every three weeks for infusions that may continue up to 24 months.
  • You will receive regular blood tests and scans of your tumor.
  • You will be regularly asked about any side effects or safety concerns you have.

If you are in the clinical trial, will you receive ivonescimab?

  • You will be randomly assigned to one of two treatment groups.
  • Half the patients will be assigned to receive ivonescimab and chemotherapy and the other half will receive pembrolizumab and chemotherapy.
  • You will be given ivonescimab, chemotherapy, and pembrolizumab by infusion.

 

Please contact your doctor for additional information.
Or email medinfo@smmttx.com

 

 

Ivonescimab is an investigational therapy that is not approved by any regulatory authority.